Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating HLX15-IV versus DARZALEX in combination with lenalidomide-dexamethasone for transplant-ineligible newly diagnosed multiple myeloma; not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• DEXAMETHASONE (Dexamethasone)
• HLX15-IV (HLX15)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Newly Diagnosed Multiple Myeloma | Phase 3 | Status: NOT_YET_RECRUITING